History of Present Illness
Ms. Champion is a female with Stage II (FIGO 2010) Grade 2 endometrioid adenocarcinoma of the endometrium, initially diagnosed in October 2020, who developed vaginal cuff recurrence in November 2022 without metastatic disease. She completed definitive salvage radiation therapy from February 2023 to April 2023, consisting of external beam radiation therapy (5000 cGy in 25 fractions) followed by 4 fractions of high-dose rate brachytherapy for a total dose of 7297 cGy to the vaginal surface. 1
She presents for scheduled surveillance follow-up and reports no major medical changes since her last visit. Her most recent pelvic examination by gynecologic oncology in April 2025 demonstrated no evidence of disease. PET-CT imaging performed in June 2025 confirmed no evidence of recurrent or metastatic disease. 1, 2
Current Disease Status
- Primary diagnosis: Stage II endometrioid adenocarcinoma, Grade 2 (October 2020)
- Recurrence: Vaginal cuff involvement (November 2022), no distant metastases
- Treatment completed: Salvage radiation therapy (February-April 2023) with curative intent 1
- Current status: No evidence of disease by clinical examination (April 2025) and imaging (June 2025) 2
- Time from completion of salvage therapy: Approximately 24 months disease-free
Surveillance Context
The patient is within the critical 3-year post-treatment window when 68-100% of endometrial cancer recurrences typically occur, warranting continued close surveillance with clinical examinations every 3-4 months. 1, 2, 3 Her excellent response to salvage radiation therapy for isolated vaginal recurrence is consistent with reported complete remission rates of 89% and 5-year survival rates of 50-70% for this clinical scenario. 1, 4